FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB N
	I = -4:

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Jones Adrian M	T2 Biosystem				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) C/O GOLDMAN SACHS & CO. L 200 WEST STREET	LC	3. Date of Earliest 7 03/24/2020					Officer (give title Other (specify below) below)			
(Street) NEW YORK NY	4. If Amendment, D	ale of C	лідіпа	ii Filea (Moni		Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
(City) (State)	(Zip)									
	e I - Non-Derivat	1		ired,					I	
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		ed (A) or tr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(11150.4)	(our .y
Common Stock <sup>(1)(2)(3)</sup>	03/24/2020		P		500	A	\$0.378	4,196,956(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	03/24/2020		S		500	D	\$0.378	4,196,456(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	03/25/2020		P		600	A	\$0.9279	4,197,056 <sup>(4)(5)</sup>	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	03/25/2020		S		600	D	\$0.9279	4,196,456(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	04/09/2020		P		1,000	A	\$0.49	4,197,456(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	04/09/2020		S		1,000	D	\$0.49	4,196,456(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		2,655	D	\$0.52	4,193,801(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		1,000	D	\$0.521	4,192,801(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		1,000	D	\$0.526	4,191,801(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		500	D	\$0.528	4,191,301(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		50	D	\$0.53	4,191,251(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		500	D	\$0.5318	4,190,751(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		100	D	\$0.5325	4,190,651(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		6,256	D	\$0.54	4,184,395(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		100	D	\$0.55	4,184,295(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		939	D	\$0.5503	4,183,356(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		P		26,200	A	\$0.5517	4,209,556 <sup>(4)(5)</sup>	I	See Footnotes <sup>(4)(5)</sup>
Common Stock <sup>(1)(2)(3)</sup>	05/06/2020		S		10,100	D	\$0.57	4,199,456(4)(5)	I	See Footnotes <sup>(4)(5)</sup>
<del></del>										

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	ate, T	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I)	Indire Benef Owne	ct icial rship		
				c	Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	(Instr.	(Instr. 4)	
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/06/2020			S		2,000	D	\$0.5701	4,197,456	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/06/2020			S		1,000	D	\$0.5702	4,196,456	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/12/2020			P		2,500	A	\$0.546	4,198,956	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/12/2020			S		2,500	D	\$0.546	4,196,456	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/19/2020			S		200	D	\$0.8314	4,196,256	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/19/2020			S		3,235	D	\$0.8318	4,193,021	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/19/2020			S		2,031	D	\$0.8325	4,190,990	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/19/2020			S		2,031	D	\$0.8326	4,188,959	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/19/2020			P		10,328	A	\$0.8329	4,199,287	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/19/2020			S		800	D	\$0.8345	4,198,487 <sup>6</sup>	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/19/2020			S		2,031	D	\$0.8347	4,196,456	(4)(5)	I	See Foot	notes <sup>(4)(5)</sup>
Common	1 Stock <sup>(1)(2)(3</sup>	)	05/20/2020			P		5,126	A	\$0.803	4,201,582	(4)(5)	I	See Foot	notes <sup>(4)(5</sup>
		Tal	ole II - Derivativ	re Securities, calls, wa								ı			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code (Instr. B)	i. Number of Derivativ Securitie Acquired A) or Disposed of (D)	er 6. E: /e (N	Date xpirati	Exercisable a on Date Day/Year)	nd 7. Ai Se Ui De Se	Title and mount of ecurities nderlying erivative ecurity (Instr. and 4)	8. Price of Derivative Security (Instr. 5)	deriva Secur Bene Owne Follor Repo	ative rities F ficially C wing ( rted caction(s)	0. Ownership Form: Direct (D) or Indirect () (Instr. 4)	11. Natur of Indire Benefici Ownersh (Instr. 4)

## **Explanation of Responses:**

1. These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.

(D)

and 5)

(A)

2. Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.

Date

Exercisable

- 3. The Reporting Person is a managing director of Goldman Sachs. Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group").
- 4. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.
- 5. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Balance of trades included in attached schedule. (See Exhibit 99.1)

/s/ Jamison Yardley, Attorney-08/03/2021 in-fact

Amount Number

Date

Expiration Date

Title

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Table 1 – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	2. Transaction Date	2A. Deemed Execution Date, if	3. Transaction Code (Instr. 8)	or	urities Acqu Disposed o nstr. 3, 4 an	f (D) `	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial Ownership
1 Tidle of Committee	(Month/	any (Month/	C-1- (D)		(A)		Reported Transaction(s)	Indirect (I)	
1. Title of Security (Instr. 3)	Day/ Year)	Day/ Year)	Code (P) or (S) V	Amount	or (D)	Price	(Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Common Stock(1) (2)(3)	05/20/2020		S	5,820	D	\$ 0.8034	4,195,762(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/20/2020		P	694	A	\$ 0.8060	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		P	5,642	A	\$ 0.7900	4,202,098(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		S	13,800	D	\$ 0.7974	4,188,298(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		P	7,458	Α	\$ 0.8000	4,195,756(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		P	1,950	Α	\$ 0.8300	4,197,706(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/26/2020		S	1,250	D	\$ 0.8300	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/28/2020		P	1,250	Α	\$ 0.8500	4,197,706(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	05/28/2020		S	1,250	D	\$ 0.8500	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P	1,781	Α	\$ 1.0700	4,198,237(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P	200	A	\$ 1.0900	4,198,437(4)(5)	I	See Footnotes(4)
Common Stock(1) (2)(3)	06/03/2020		P	1,051	Α	\$ 1.1000	4,199,488(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		s	10,000	D	\$ 1.1314	4,189,488(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P	4,835	Α	<b>\$ 1.1500</b>	4,194,323(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/03/2020		P	2,133	Α	\$ 1.1600	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/04/2020		P	7,500	Α	\$ 1.2900	4,203,956(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/04/2020		s	7,500	D	\$ 1.2900	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/08/2020		P	3,200	A	\$ 1.3400	4,199,656(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/08/2020		S	5,474	D	\$ 1.3442	4,194,182(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/08/2020		P	2,274	A	\$ 1.3500	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		S	200	D	\$ 1.2900	4,196,256(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		P	38,963	A	\$ 1.3629	4,235,219(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		S	38,963	D	\$ 1.3629	4,196,256(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		P	3,800	A	\$ 1.3633	4,200,056(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/09/2020		S	3,600	D	\$ 1.3674	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/10/2020		P	163,073	A	\$ 1.7000	4,359,529(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/10/2020		S	163,073	D	\$ 1.7000	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/10/2020		P	163,073	Α	\$ 1.7317	4,359,529(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/10/2020		S	163,073	D	\$ 1.7317	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		s	2,000	D	\$ 1.5000	4,194,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		P	2,000	Α	\$ 1.5300	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		S	2,000	D	\$ 1.5300	4,194,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		s	300	D	\$ 1.5800	4,194,156(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		P	46,050	Α	<b>\$ 1.5955</b>	4,240,206(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/11/2020		s	43,750	D	\$ 1.6000	4,196,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/15/2020		P	47,750	A	\$ 1.6100	4,234,206(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/15/2020		S	47,750	D	\$ 1.6100	4,186,456(4)(5)	I	See Footnotes(4) (5)

Common Stock(1) (2)(3)	06/16/2020	P	2,000	A	<b>\$ 1.5000</b>	4,188,456(4)(5)	I	See Footnotes(4)
Common Stock(1) (2)(3)	06/16/2020	S	2,000	D	\$ 1.5000	4,186,456(4)(5)	I	See Footnotes(4)
Common Stock(1) (2)(3)	06/17/2020	S	708	D	\$ 1.4410	4,185,748(4)(5)	I	See Footnotes(4)
Common Stock(1) (2)(3)	06/17/2020	P	2,708	A	<b>\$ 1.4476</b>	4,188,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/17/2020	S	2,000	D	<b>\$ 1.4500</b>	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/29/2020	P	300	A	\$ 1.2900	4,186,756(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/29/2020	s	300	D	\$ 1.2900	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/29/2020	P	3,973	A	\$ 1.3300	4,190,429(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/29/2020	s	5,000	D	\$ 1.3341	4,185,429(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	06/29/2020	P	1,027	A	\$ 1.3500	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/01/2020	P	250,000	A	\$ 1.7542	4,436,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/01/2020	S	250,000	D	\$ 1.7542	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/01/2020	P	47,586	A	\$ 1.9254	4,234,042(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/01/2020	P	250,000	A	\$ 1.9362	4,484,042(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/01/2020	S	297,586	A	\$ 1.9345	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/07/2020	P	350	A	\$ 1.2400	4,186,806(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/07/2020	S	350	D	\$ 1.2400	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/08/2020	S	50	D	\$ 1.2900	4,186,406(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/08/2020	P	350	A	\$ 1.2943	4,186,756(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/08/2020	s	300	D	\$ 1.2950	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/21/2020	P	500	A	\$ 1.7400	4,267,807(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/21/2020	s	500	D	\$ 1.7400	4,267,307(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/22/2020	P	1,500	A	\$ 1.6813	4,187,956(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/22/2020	s	1,500	D	\$ 1.6813	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/23/2020	P	3,000	A	\$ 1.6883	4,189,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/23/2020	s	3,000	D	\$ 1.6883	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/24/2020	P	7,500	A	\$ 1.5500	4,193,956(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/24/2020	S	8,211	D	\$ 1.5508	4,185,745(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/24/2020	P	100	A	\$ 1.5550	4,185,845(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/24/2020	P	611	A	\$ 1.5600	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/28/2020	P	7,523	A	\$ 1.4800	4,193,979(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	07/28/2020	S	7,523	D	\$ 1.4800	4,186,456(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	08/03/2020	P	46,565	A	\$ 1.6473	4,233,021(4)(5)	I	See Footnotes(4) (5)
Common Stock(1) (2)(3)	08/03/2020	S	46,565	D	\$ 1.6473	4,186,456(4)(5)	I	See Footnotes(4) (5)

## Explanation of Responses:

- 1. These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.
- 2. Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
- 3. The Reporting Person is a managing director of Goldman Sachs. Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group").
- 4. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.
- 5. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.